Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Sep 26, 2022--
The "Peripheral Neuropathy Treatment Market, by Indication, by Treatment and Non-Pharmacological Therapies, by End-user, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
Peripheral neuropathy is a disorder of the peripheral nerves. These nerves send messages between the central nervous system, the brain and the spinal cord, and the rest of the body. Peripheral neuropathy can result from traumatic injuries, infections, metabolic problems, inherited causes, and exposure to toxins. One of the most common causes is diabetes.
Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy. Individual with peripheral neuropathy generally describe the pain as stabbing, burning or tingling. In many cases, symptoms improve, especially if caused by a treatable condition. Medications such as Lyrica, Cymbalta, etc can reduce the pain of peripheral neuropathy.
Market Dynamics
Key players operating in the global peripheral neuropathy treatment market are focusing on adoption growth strategies such as product launch, and approval which are expected to drive the market growth during the forecast period. For instance, in July 2019, Alembic Pharmaceuticals Limited, an Indian pharmaceutical company, announced that it received the approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Pregabalin Capsules that is used for peripheral neuropathic pain.
Moreover, various government agencies focusing on investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy which is expected to drive the market growth over forecast period.
For instance, in November 2018, the U.S. National Cancer Institute awarded/invested US$ 2.3 Mn in Indiana University School of Medicine, a research institute in the U.S. The investment was made in Indiana University School of Medicine to accelerate the research and development of small, targeted molecule called APX3330 to prevent or reverse chemotherapy induced peripheral neuropathy (CIPN) caused by cancer drugs.
Key features of the study:
Detailed Segmentation:
Global Peripheral Neuropathy Treatment Market, By Indication :
Global Peripheral Neuropathy Treatment Market, By Treatment :
Global Peripheral Neuropathy Treatment Market, By End User :
Global Peripheral Neuropathy Treatment Market, By Region
Company Profiles:
Key Topics Covered:
1. Research Objectives and Assumptions
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. Global Peripheral Neuropathy Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
5. Global Peripheral Neuropathy Treatment Market, By Indication, 2017-2030, (US$ Mn)
6. Global Peripheral Neuropathy Treatment Market, By Treatment, 2017-2030, (US$ Mn)
7. Global Peripheral Neuropathy Treatment Market, By End User, 2017-2030, (US$ Mn)
8. Global Peripheral Neuropathy Treatment Market, By Region, 2017-2030, (US$ Mn)
9. Competitive Landscape
10. Section
For more information about this report visit https://www.researchandmarkets.com/r/wl73ah
View source version on businesswire.com:https://www.businesswire.com/news/home/20220926005535/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 09/26/2022 09:44 AM/DISC: 09/26/2022 09:44 AM
http://www.businesswire.com/news/home/20220926005535/en